Passage Bio (PASG) Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization
Passage Bio, Inc. (PASG) specializes in developing gene therapies for brain pathologies, leveraging exclusive patents and orphan drug status to ensure long-term dominance. The company invests massive resources into the study of viral vectors, backed by a robust scientific foundation. A stable team of experts guarantees the protection of its intellectual capital. This market valuation chart for Passage Bio, Inc. (PASG) on GURU.Markets shows a value of 0.00.
PASG (passagebio.com): analytical breakdowns and indicator data
- market price and analyst price targets:
- market capitalization details:
- book value of equity indicators:
- company liabilities and liquidity data:
Total Debt to Capital Passage Bio, Inc.|PASG - Long-Term Liabilities to Capital|Short-Term Debt to Equity Ratio Passage Bio|PASG - Aggregate Debt Obligations|Debts to Book Capitalization Passage Bio, Inc.|PASG - Company Long-Term Debt|Company Short-Term Debts Passage Bio|Quick Liquidity passagebio.com
- financial results and valuation multiples details:
PASG - Company Net Income|Future Profit Passage Bio, Inc.|PASG - Company Value to Net Income|Forward P/E Multiple Passage Bio|PASG - Growth-Adjusted Market Cap to Net Income|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Passage Bio, Inc.|PASG - Operating profit before amortization|Net earnings per share (EPS TTM) Passage Bio|PASG - Net earnings per share for the last 12 months|Year-over-year net earnings per share growth for the last 12 months passagebio.com|PASG - Expected net earnings per share growth this year|Net earnings per share growth forecast for next year Passage Bio, Inc.
Summary company analysis:Passage Bio Corp PASG
The EV/EBITDA multiple determines the business value relative to its operating profit before depreciation, taxes, and interest, allowing for an assessment of the asset's real value regardless of debt load. By analyzing the EV/EBITDA multiple on a time chart, an investor correlates the capital-intensive R&D expenditures of Passage Bio, Inc. (PASG) and the patent protection of AAV vectors with strict FDA oversight, which confirms the company's fundamental resilience under regulatory pressure.
Who Passage Bio, Inc. competes with
Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Biogen Corp BIIB|Total Company Value to Operating Income Before Depreciation Ratio Neurocrine Corp (NBIX)|RGC - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Total Company Value to Operating Income Before Depreciation Ratio axsome.com AXSM|ACAD: EV/EBITDA Multiple|Xenon Pharmaceuticals Inc. (XENE) - EV/EBITDA Multiple|VKTX (Viking Pharma) - EV/EBITDA Multiple|SUPN - Enterprise Value to EBITDA Multiple|EV/EBITDA Multiple CPRX|DNLI - Company Value to EBITDA|Harmony Biosciences Holdings, Inc. - Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation BHVN|Amylyx - EV/EBITDA Multiple|TRVI: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|PRAX: EV/EBITDA Multiple|AVXL - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization CeriBell|Company Value to EBITDA Prothena Corporation PLC PRTA|Enterprise Value to EBITDA Ratio ALEC (Alector, Inc.)|ANNX (Annexon Biosciences Inc.) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple OMER (Omeros)|Total Company Value to Operating Income Before Depreciation Ratio neurogene.com (NGNE)|ACIU - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|VYGR (Voyager Therapeutics Inc) - Enterprise Value to Operating Income Before Depreciation|NMRA: EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio Scilex Holding Company, Inc.|Enterprise Value to EBITDA Ratio TVGN|Alpha Cognition Corp (ACOG) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Cognition Therapeutics, Inc. (CGTX)|IKT: Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple SAVA (Cassava)|EV/EBITDA Multiple Assertio Holdings ASRT|COYA - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Total Company Value to Operating Income Before Depreciation Ratio Vistagen Therapeutics VTGN|OVID: EV/EBITDA Multiple|Enterprise Value to EBITDA Multiple Acumen Pharmaceuticals Inc. ABOS|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization CervoMed Inc|Enterprise Value to Operating Income Before Depreciation ATHE (Alterity Therapeutics Ltd)|EV/EBITDA Multiple CLNN|PEPG - Company Value to EBITDA|Jupiter Neurosciences - Enterprise Value to EBITDA Ratio|EV/EBITDA Multiple Relmada Therapeutics Inc RLMD|ANVS - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Business Value to Operating Income Before Depreciation GRCE (Grace Therapeutics, Inc.)|Firefly Neuroscience, Inc (AIFF) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA Klotho Neurosciences (KLTO)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization NeuroSense Therapeutics Ltd|Reviva Pharmaceuticals Holdings Inc. - Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple MTVA|EV/EBITDA Multiple NeurAxis Inc (NRXS)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Helius Medical Technologies HSDT|Total Company Value to Operating Income Before Depreciation Ratio Neuphoria Therapeutics, Inc. (NEUP)|NERV - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Total Company Value to Operating Income Before Depreciation Ratio Athira Pharma Inc ATHA|ADXN: EV/EBITDA Multiple|Alzamend Neuro (ALZN) - EV/EBITDA Multiple|CYCN (Cyclerion Therapeutics Inc.) - EV/EBITDA Multiple|PTIX - Enterprise Value to EBITDA Multiple|EV/EBITDA Multiple KTTA|CRGT - Company Value to EBITDA|Avenue Therapeutics, Inc - Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation BCLI|Cara Therapeutics, Inc. - EV/EBITDA Multiple|CHRO: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|ELYM: EV/EBITDA Multiple|ITCI - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Longboard Pharma|Company Value to EBITDA Marinus Pharma MRNS|Enterprise Value to EBITDA Ratio NKGN (NKGen Biotech, Inc.)|NRBO (neurobopharma.com) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple SAGE (Sage Therapeutics)|Total Company Value to Operating Income Before Depreciation Ratio Synaptogenix Inc. (SNPX)|TRVN - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|VIGL (Vigil Neuroscience) - Enterprise Value to Operating Income Before Depreciation|WENA: EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio cerevel.com
